Scaling human pluripotent stem cell expansion and differentiation: are cell factories becoming a reality?

Written by Regenerative Medicine

Commentary by Morgan Alexander, Chris Denning, Asha K Patel et al. (University of Nottingham, UK) on the advances of human pluripotent stem cell derivatives being utilized within regenerative medicine and the options to overcome potential challenges in the future.

Recent advances within regenerative medicine suggest that human pluripotent stem cells may soon be employed within clinical settings, prompting attempts to resolve the challenges involved in large-scale manufacture of cell therapies. Laboratory culture techniques cannot always translate into the clinical setting, meaning processes such as culture systems need to be developed for scaled-up manufacture.

This Commentary by James GW Smith,, Adam D Celiz, Asha K Patel, Robert D Short, Morgan R Alexander and Chris Denning from University of Nottingham (UK) discusses current technology within regenerative medicine in regards to utilizing human pluripotent stem cells as an effective treatment method, covering the recent Phase I clinical trials for potential spinal cord injury and macular degeneration therapy and the implications of this study. Additionally, they comment on the possibility of manufacturing these cells in way that complies with regulations while being cost effective, to remain financially compatible with healthcare providers.

Smith JGW, Celiz AD, Patel AK, Short RD, Alexander MR, Denning C. Scaling human pluripotent stem cell expansion and differentiation: are cell factories becoming a reality? Regen. Med. 10(8), 925—930 (2015).

Authors for correspondence: [email protected] and [email protected]